Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.52 |
| ▸ | IDO1 | P14902 | 2/20 | 0.44 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 4/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | MPO | P05164 | 2/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
| ▸ | DAO | P14920 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2096285 | 0.80 | TAAR1 (0.52) | TAAR1IDO1AOC3MAOBMPO | |
| SCHEMBL14877173 | 0.79 | TAAR1 (0.56) | TAAR1IDO1AOC3MAOBMPO | |
| SCHEMBL8235305 | 0.79 | TAAR1 (0.56) | TAAR1IDO1AOC3MAOBMPO | |
| SCHEMBL28694560 | 0.79 | TAAR1 (0.60) | TAAR1IDO1AOC3MAOBMPO | |
| SCHEMBL3243413 | 0.78 | IDO1 (0.47) | IDO1MAOBALOX5DAOALDH1A1 | |
| SCHEMBL4514414 | 0.76 | CYP1A2 (0.44) | HPGDALDH1A1 | |
| SCHEMBL7563209 | 0.75 | TAAR1 (0.56) | TAAR1IDO1AOC3MAOBMPO | |
| SCHEMBL8526001 | 0.75 | TAAR1 (0.75) | TAAR1IDO1AOC3MAOBMPO | |
| SCHEMBL2090266 | 0.74 | TAAR1 (0.50) | TAAR1IDO1AOC3MAOBMPO | |
| SCHEMBL7593751 | 0.73 | THRA (0.37) | LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7745438-B2 | 3-(2-acylamino-1-hydroxyethyl)-morpholine derivatives and their use as bace inhibitors | ELI LILLY AND COMPANY (US) | 2010-06-29 | — | — | US | disclosed |
| US-20070225267-A1 | 3-(2-Acylamino-1-Hydroxyethyl)-Morpholine Derivatives and Their Use as Bace Inhibitors | ELI LILLY AND COMPANY | 2007-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225267-A1 | 3-(2-Acylamino-1-Hydroxyethyl)-Morpholine Derivatives and Their Use as Bace Inhibitors | BACE1, BACE2, APP | TAAR1 2077/4885IDO1 1979/4885AOC3 267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.